BioCentury
ARTICLE | Company News

Management tracks: Gilead's McHutchison joins Assembly as CEO; plus Lilly, Vor, HiberCell, insitro and more

August 7, 2019 11:54 PM UTC

Assembly Biosciences Inc. (NASDAQ:ASMB) gained $2.39 (20%) to $14.25 Wednesday after hiring John McHutchison as president and CEO, succeeding Derek Small. Gilead Sciences Inc. (NASDAQ:GILD) announced last month that McHutchison would step down as CSO and head of R&D. Small, who co-founded the HBV company, will return to Luson Bioventures as managing director and will remain on Assembly's board (see "Gilead CSO McHutchison, Two Others, Out").

Levi Garraway has resigned as SVP of oncology research and early phase development at Eli Lilly and Co. (NYSE:LLY) to pursue other opportunities. He is succeeded in the interim by the CEO of Lilly’s Loxo Oncology Inc. subsidiary, Josh Bilenker. Garraway’s departure was one of several management moves unveiled Wednesday by the pharma, which also said SVP of Corporate Business Development Darren Carroll will retire at the end of the month and SVP and Treasurer Phil Johnson will begin overseeing M&A. The pharma also announced two promotions: Frank Cunningham to SVP from VP of managed healthcare services and Heather Wasserman to VP of corporate BD from senior director, external innovation...